Sino Biopharmaceutical Limited Stock price

Equities

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. 03:08:14 2024-02-29 am EST 5-day change 1st Jan Change
3.13 HKD +2.29% Intraday chart for Sino Biopharmaceutical Limited -1.26% -9.80%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site

Financials

Sales 2023 * 30.31B 4.22B 33B Sales 2024 * 33.36B 4.64B 36.32B Capitalization 51.77B 7.2B 56.36B
Net income 2023 * 3.05B 424M 3.32B Net income 2024 * 3.38B 470M 3.68B EV / Sales 2023 * 1.58 x
Net cash position 2023 * 3.9B 542M 4.24B Net cash position 2024 * 7.18B 999M 7.82B EV / Sales 2024 * 1.34 x
P/E ratio 2023 *
17.9 x
P/E ratio 2024 *
16.2 x
Employees 26,079
Yield 2023 *
2.06%
Yield 2024 *
2.39%
Free-Float 51.86%
More Fundamentals * Assessed data
Dynamic Chart
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart CI
Sino Biopharmaceutical's Anti-Cancer Drug Under Priority Review in China MT
Sino Biopharm Units Sell 67% Stake in Pharmaceutical Company MT
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 million RE
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical Co., Ltd from Sino Biopharmaceutical Limited for CNY 1.8 billion. CI
Sino Biopharmaceutical Files for Chinese Launch of Obeticholic Acid Tablets MT
China Outlook, Profit-Taking Roil Asian Stock Markets MT
Sino Biopharmaceutical Repurchases Over 78 Million Shares Under Buyback Plan MT
Sino Biopharm's Lung Cancer Drug Added to China's Priority List for Evaluation MT
Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553) CI
Sino Biopharmaceutical Trustee Buys Back 2 Million Shares MT
Sino Biopharmaceutical Trustee Repurchases Shares MT
Chinese Regulator Grants Marketing Approval for Sino Biopharmaceutical’s Immune Thrombocytopenia Drug MT
Sino Biopharm Begins Phase 3 Trial for Type 2 Diabetes Injectable; Shares Fall 4% MT
Sino Biopharmaceutical Trustee Repurchases 5 Million Shares MT
More news
1 day+2.29%
1 week-1.26%
Current month+11.39%
1 month+6.46%
3 months-16.31%
6 months+1.29%
Current year-9.80%
More quotes
1 week
3.04
Extreme 3.04
3.23
1 month
2.71
Extreme 2.71
3.23
Current year
2.71
Extreme 2.71
3.49
1 year
2.57
Extreme 2.57
4.73
3 years
2.57
Extreme 2.57
9.69
5 years
2.57
Extreme 2.57
11.24
10 years
1.70
Extreme 1.6978
11.24
More quotes
Managers TitleAgeSince
Chief Executive Officer 29 19-10-22
Founder 72 00-02-01
Director of Finance/CFO 53 -
Members of the board TitleAgeSince
Founder 72 00-02-01
Director/Board Member 60 04-12-31
Director/Board Member 54 95-07-31
More insiders
Date Price Change Volume
24-02-29 3.13 +2.29% 59 223 416
24-02-28 3.06 -2.55% 31,303,190
24-02-27 3.14 -0.63% 45,785,540
24-02-26 3.16 +0.64% 34,289,640
24-02-23 3.14 -0.95% 40,166,990

Delayed Quote Hong Kong S.E., February 29, 2024 at 03:08 am EST

More quotes
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
2.814 CNY
Average target price
4.664 CNY
Spread / Average Target
+65.76%
Consensus
  1. Stock
  2. Equities
  3. Stock Sino Biopharmaceutical Limited - Hong Kong S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW